| Name | Title | Contact Details |
|---|
GRACE NETWORK is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Med Fusion is a Lewisville, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage`s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage`s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.
MMI Genomics is a Davis, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InnovaPrep is engaged in product development, manufacturing, sales, service, and related out-licensing of a collection of novel technologies enabling rapid detection of biological particles and pathogens. Our core business is biological sample collection, concentration and preparation. The company has commercialized a collection of market-disruptive platform technologies for rapid, automated concentration of biological particles. InnovaPrep`s 35 pending and awarded patents apply to highly efficient collection, recovery, and concentration of biological particles from air, surfaces, and liquids. Our elution process underlies many of these patents and enables recovery of particles from filters, membranes, surfaces, and objects. The primary utility for these technologies is to greatly improve the way biological samples, especially those containing pathogenic organisms, are collected and prepared for analysis beyond the state-of-the-art. These technologies fill a critical void that currently severely limits application of the most advanced biological detection systems to the billions of microbiological tests performed annually. Markets served: Biodefense, food safety, water safety, biopharma, clinical research, animal health, environmental monitoring and others.